Columvi Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of conventional lymphoma therapies, advancement in monoclonal antibody engineering, approval of cd20 targeted treatments, oncology specialist adoption, improved survival outcomes.

The growth in the forecast period can be attributed to growth in relapsed lymphoma cases, expansion of bispecific platforms, combination immunotherapy research, specialty oncology center growth, precision oncology investments. Major trends in the forecast period include rising adoption of bispecific antibody therapies, expansion of immunotherapy in relapsed lymphoma, focus on t cell redirecting treatments, hospital based advanced oncology care, growing use of targeted cd20 therapies.

The growing incidence of hematologic malignancies is expected to drive the expansion of the Columvi market in the coming years. Hematologic malignancies are cancers that originate from blood-forming cells, primarily affecting the bone marrow and lymphatic system. The rising number of cases is attributed to factors such as an aging population, increased exposure to carcinogens, lifestyle changes including obesity, improved diagnostic methods, and geographic differences in incidence rates. Columvi is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and large B-cell lymphoma (LBCL) after two or more systemic therapies. For example, in March 2024, the Leukaemia & Lymphoma Society, a US-based professional organization, projected that approximately 187,740 individuals in the US would be diagnosed with leukemia, lymphoma, or myeloma in 2024, representing 9.4% of the total 2,001,140 new cancer cases expected nationwide. Consequently, the increasing incidence of hematologic malignancies is fueling the growth of the Columvi market.

The expanding aging population is also expected to support the growth of the Columvi market. The aging population refers to a demographic group with a higher proportion of individuals aged 65 and older, resulting from increased life expectancy and declining birth rates. This demographic is growing due to healthcare advancements and improved living standards that extend life expectancy, combined with lower birth rates in many regions. Columvi provides the aging population with an effective treatment option for relapsed or refractory DLBCL, a condition more prevalent among older adults, offering targeted and durable therapeutic strategies. For instance, in October 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that by 2030, one in six people worldwide will be aged 60 years or older, with this population rising from 1 billion in 2020 to 1.4 billion. By 2050, the number of individuals aged 60 and above is projected to double, reaching 2.1 billion, while the population aged 80 years and older is expected to triple to 426 million. Therefore, the growing aging population is contributing to the expansion of the Columvi market.

A key trend in the Columvi market is the development of advanced therapies, such as bispecific T-cell engagers (BiTEs), for treating adult patients with relapsed or refractory DLBCL and LBCL. BiTEs are engineered proteins that simultaneously bind T cells and cancer cells, redirecting the immune system to target and eliminate tumor cells. For instance, in June 2023, Roche, a Switzerland-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Columvi (glofitamab-gxbm) for adults with relapsed or refractory DLBCL not otherwise specified or LBCL arising from follicular lymphoma after two or more systemic therapies. This approval was based on positive results from the phase I/II NP30179 study, which evaluated Columvi as a fixed-duration therapy over 8.5 months in 132 patients. Among these patients, 30% had previously received CAR T-cell therapy, and 83% were refractory to their most recent treatment. The study demonstrated durable remission, with an overall response rate (ORR) of 56% (74/132) and a complete response (CR) rate of 43% (57/132).

Major companies operating in the columvi market are F. Hoffmann-La Roche Ltd.

North America was the largest region in the columvi market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the columvi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the columvi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the columvi market by increasing costs related to biologic manufacturing equipment, clinical grade antibodies, and infusion delivery systems. These impacts are most pronounced in hospital oncology pharmacies in north america and europe. Import duties have influenced pricing of advanced immunotherapies. Supply chain timelines have also faced regulatory related delays. At the same time, tariffs are encouraging localized antibody manufacturing and strengthening oncology drug supply infrastructure.

The columvi market research report is one of a series of new reports that provides columvi market statistics, including columvi industry global market size, regional shares, competitors with a columvi market share, detailed columvi market segments, market trends and opportunities, and any further data you may need to thrive in the columvi industry. This columvi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Columvi (glofitamab-gxbm) is a prescription medication for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults who have undergone at least two prior therapies. It is a bispecific monoclonal antibody that binds CD20 on B-cells and CD3 on T-cells, triggering an immune response against cancer cells. Administered through intravenous infusion, it provides a novel immunotherapy option for difficult-to-treat B-cell lymphomas.

Columvi is primarily indicated for non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). NHL is a cancer that develops in the lymphatic system, including the lymph nodes, spleen, and bone marrow. The medication can be used as bispecific antibody therapy or targeted CD20-CD3 therapy and is distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies.

The columvi market consists of sales of monoclonal antibodies, bispecific antibodies, small molecule drugs, and diagnostic products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.